Drug intelligence / Profile preview

omega-3 + risperidone

Development stage
Preclinical
Lead developer
GSK
Modality
Small Molecules
Administration
Oral
01

Overview

This is a combination of omega-3 polyunsaturated fatty acids (commonly found in fish oil) and risperidone, an atypical antipsychotic. Omega-3 fatty acids are known for their antioxidant and anti-inflammatory properties and have been studied as adjunctive therapy in neuropsychiatric disorders. Risperidone acts primarily as an antagonist at dopamine D2 and serotonin 5-HT2A receptors, reducing symptoms of schizophrenia and bipolar disorder. Preclinical studies suggest that the combination may reduce oxidative stress markers (such as MDA and TNF-alpha) more effectively than either agent alone in animal models of schizophrenia[2][3]. There is no evidence this specific combination is marketed under a unique brand name or approved formulation; it has been studied experimentally for potential synergistic effects on behavior and brain biochemistry.

Other names
omega-3 fatty acids + risperidonefish oil + risperidone
02

Targets

HTR2A (Serotonin receptor 5-HT2A)RXRA (Retinoid X receptor alpha)MAPK14 (p38 mitogen-activated protein kinase alpha)JNK (Mitogen-activated protein kinase kinase kinase family)DRD2 (Dopamine D2 Receptor)

Beyond the preview

Go deeper on omega-3 + risperidone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on omega-3 + risperidone.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call